By NewsDesk @bactiman63

Boston-based biopharmaceutical company, Paratek Pharmaceuticals announced the novel, once-daily oral and intravenous antibiotic NUZYRA® (omadacycline) has recently been added to the Center for Disease Control and Prevention’s (CDC) updated report, “Antimicrobial Treatment and Prophylaxis of Plague: Recommendations for Naturally Acquired Infections and Bioterrorism Response“.

Bipolar staining of a plague smear prepared from lymph aspirated from an adenopathic lymph node, or bubo, of a plague patient./CDC

NUZYRA was added as an alternative agent for the treatment, pre-exposure prophylaxis, and postexposure prophylaxis of primary bubonic and pharyngeal plague infections in adults 18 years of age and over.

“We believe the inclusion of NUZYRA in the updated CDC recommendations provides additional validation of the potential clinical utility of this modernized tetracycline antibiotic to help address these types of public health emergencies including protecting our civilian and military personnel as a medical countermeasure,” said Randy Brenner, Chief Development and Regulatory Officer. “The development of new antibiotics that are effective against possible biosecurity threats is vital to ensuring our national security particularly at a time when antimicrobial resistance is growing.”

The CDC conducted a series of systematic literature reviews on human treatment of plague and other relevant topics to collect a broad evidence base to assist in the development of a comprehensive set of updated recommendations.